Isofagomine Inhibits Multiple TcdB Variants and Protects Mice from -Induced Mortality.

causes life-threatening diarrhea and is one of the leading causes of nosocomial infections. During infection, releases two gut-damaging toxins, TcdA and TcdB, which are the primary determinants of disease pathogenesis and are important therapeutic targets. Once in the cytosol of mammalian cells, TcdA and TcdB use UDP-glucose to glucosylate host Rho GTPases, which leads to cytoskeletal changes that result in a loss of intestinal integrity. Isofagomine inhibits TcdA and TcdB as a mimic of the glucocation transition state of the glucosyltransferase reaction. However, sequence variants of TcdA and TcdB across the clades of infective continue to be identified, and therefore, evaluation of isofagomine inhibition against multiple toxin variants is required. Here, we show that isofagomine inhibits the glucosyltransferase domain of multiple TcdB variants and protects TcdB-induced cell rounding of the most common full-length toxin variants. Furthermore, we demonstrate that isofagomine protects against -induced mortality in two murine models of infection. Isofagomine treatment of mouse infection also permitted the recovery of the gastrointestinal microbiota, an important barrier to preventing recurring infection. The broad specificity of isofagomine supports its potential as a prophylactic to protect against -induced morbidity and mortality.